IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Exelixis, Inc. focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Its products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma.
Manufacturing
Pharmaceutical Products
$10.79B
1.2K
SOUTH SAN FRANCISCO, California
Michael M. Morrissey
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = EXEL ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$EXEL EXELIXIS, INC. | 63 | 83 | 78 | 56 | 16.2x | 13.6x | 32.3% | 24.7% | 96.6% | 36.1% | 30.6% | 10.8% | 0.0% | 31.0x | $10.8B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
EXELIXIS, INC. (EXEL) receives a "Hold" rating with a composite score of 62.8/100. It ranks #440 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Michael M. Morrissey
Chief Executive Officer
Labor Force
1,220
83
40
81
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for EXEL
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for EXEL.
View All RatingsYOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Improving capital utilization rates confirmed
High margin volatility — erratic forensic earnings quality
ROE proxy 32.3% (sector -2.5%)
GM 97% vs sector 43%, OM 36% vs sector 1%
Capital turnover N/A, R&D intensity 35.5%
Rev growth 11%, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns EXELIXIS, INC. a Hold rating, with a composite score of 62.8/100 and 3 out of 5 stars. Ranked #440 of 7,333 stocks, EXEL presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
EXEL earns a quality score of 83/100, indicating above-average business quality. The company reports a return on equity of 32.3% (sector avg: -2.5%), gross margins of 96.6% (sector avg: 42.5%), net margins of 30.6% (sector avg: -0.2%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
EXEL carries a solid value score of 78/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 16.24x, an EV/EBITDA of 13.64x, a P/B ratio of 5.24x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
With an investment score of 40/100, EXEL exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 10.8% vs. a sector average of 5.9% and a return on assets of 24.7% (sector: -0.1%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
EXEL demonstrates moderate momentum with a score of 56/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 10.8% year-over-year, while a beta of 0.63 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
EXEL shows good financial stability with a score of 81/100. Key stability metrics include a beta of 0.63 and a debt-to-equity ratio of 31.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
EXELIXIS, INC.'s short interest score of 15/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 31.00x). At $10.8B (large-cap), EXEL carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
EXELIXIS, INC. is a large-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #440 of 7,333 overall (94th percentile). Key comparisons include ROE of 32.3% exceeding the -2.5% sector median and operating margins of 36.1% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While EXEL currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Quality (83) vs Short Int. (15) — closing this gap could shift the rating.
EV/EBITDA 19% ABOVE SECTOR MEDIAN
ROE 1402% BELOW SECTOR MEDIAN
Gross Margin 127% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF OCT 3, 2025 (Q3 FY2025)
We rate EXELIXIS, INC. (EXEL) as a Hold with a composite score of 62.8/100 at a current price of $44.60. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in quality (83th percentile) and stability (81th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (40th percentile) and momentum (56th percentile) tempers our overall conviction. We assign a Narrow Moat rating (63/100), Low uncertainty, and Exemplary capital allocation.
Key items to watch: quarterly earnings execution and sector-level competitive dynamics. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
EXELIXIS, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 62.8/100 places it at rank #440 in our full 7,333-stock universe. With a $10.8B market capitalization, EXELIXIS, INC. operates at meaningful scale within the Manufacturing sector, providing competitive advantages in distribution, procurement, and customer reach.
Revenue is growing at 11%, though momentum at the 56th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 97% (+54.1pp vs sector) narrow to operating margins of 36% (+34.8pp vs sector) and net margins of 30.6%, yielding a gross-to-net conversion rate of 32%. This efficient conversion suggests well-controlled operating costs and limited margin leakage between the gross and net levels.
At a current price of $44.60, EXELIXIS, INC. appears undervalued relative to its fundamentals. Our value factor score of 78/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The stock screens as attractively priced on a majority of these measures, suggesting the market may be underappreciating the underlying fundamentals.
The stock currently trades at a P/E of 16.2x (a 27% discount to the sector median of 22.3x), EV/EBITDA of 13.6x (near the sector median), P/B of 5.2x, P/S of 5.0x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
Gross margins of 97% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 32.3% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Revenue growth of 11% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A value factor score of 78/100 suggests the market is underpricing these fundamentals, creating a potential margin of safety for new investors.
Return on assets of 24.7% indicates efficient deployment of the full asset base, not just equity capital.
We assign a Low uncertainty rating to EXELIXIS, INC.. The company exhibits strong financial stability with a beta of 0.63, conservative leverage (31% D/E), and a stability factor in the 81th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
Specific risk factors that inform our assessment include: low beta of 0.63 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 81th percentile and quality factor at the 83th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 97% provide a buffer against cost pressures; above-average stability (81th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate EXELIXIS, INC.'s capital allocation as Exemplary. Management demonstrates a strong track record of balancing reinvestment with shareholder returns, evidenced by returns on equity of 32.3%, disciplined leverage (31% D/E), best-in-class net margins of 30.6%. Exemplary allocators typically generate returns on equity above 20% while maintaining debt-to-equity below 50% — EXELIXIS, INC. meets this high bar.
The balance sheet remains conservatively managed, providing financial flexibility for opportunistic investments while maintaining a margin of safety for shareholders. We note that the combination of 24.7% return on assets and controlled leverage suggests management is deploying capital at rates well above the cost of capital — the hallmark of exemplary stewardship.
In summary, EXELIXIS, INC. receives a Hold rating with a composite score of 62.8/100 (rank #440 of 7,333). Our quantitative framework assigns a Narrow Moat (63/100, trend: stable), Low uncertainty, and Exemplary capital allocation. The average factor score across quality, value, momentum, stability, and investment is 67/100.
Our analysis supports a neutral stance on EXELIXIS, INC.. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign EXELIXIS, INC. a Narrow Moat rating with a composite moat score of 63/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that EXELIXIS, INC. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 19.8/20.
The strongest moat sources are margin superiority (19.8/20) and economic value creation (14.9/20). GM 97% vs sector 43%, OM 36% vs sector 1%. ROE proxy 32.3% (sector -2.5%). These pillars form the core of EXELIXIS, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (7/20) and financial resilience (9.7/20). Capital turnover N/A, R&D intensity 35.5%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect EXELIXIS, INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 97% providing a solid profitability foundation, operating margins of 36% reflecting effective cost management, moderate revenue growth of 11%. The margin cascade from 97% gross to 36% operating to 30.6% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 83th percentile.
The margin profile shows gross margins of 97%, operating margins of 36%, net margins of 30.6%. Return metrics include ROE of 32.3% and ROA of 24.7%. Relative to the Manufacturing sector, gross margins are 54.1 percentage points above the sector median of 43%, and ROE of 32.3% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 31%, revenue growth of 11%. The sector median D/E is 0%, putting EXELIXIS, INC. at higher leverage than the typical peer. The combination of low leverage and healthy profitability provides significant financial resilience and strategic optionality.
Even high-quality stocks face risks from valuation compression, competitive disruption, or macro shocks that are difficult to quantify in advance.
Exelixis, Inc. (EXEL) is highlighted as a strong biotechnology company focused on novel cancer therapies, with a market cap of $11.7 billion and current stock price of $43.63. The company shows stable market performance, attractive valuation, robust revenue growth, and strong financial health, including a high return on equity and substantial free cash flow. Despite mixed analyst ratings, an average price target of $47.17 suggests an 8.11% potential upside, making it a compelling prospect for growth-oriented investors due to its strategic partnerships and promising pipeline.
H.C. Wainwright increased its price target for Exelixis (NASDAQ:EXEL) to $54 from $52, maintaining a Buy rating after the biopharmaceutical company reported better-than-expected Q4 2025 diluted net income of $0.88 per share. This positive adjustment is supported by InvestingPro data indicating the stock is trading below its Fair Value with a low PEG ratio. The firm also projected an increase in full-year 2026 net earnings to $3.15 per share, citing the company's strong cash position.
Exelixis, Inc. reported strong Q4 and full-year 2025 financial results, with US cabozantinib franchise net product revenues growing 17% to $2.12 billion for the full year. The company is advancing zanzalintinib as its next oncology franchise, with an NDA accepted for the ZanzaAteza combination in third-line plus colorectal cancer and seven ongoing pivotal trials. Exelixis aims to build a multi-franchise business in solid tumor oncology, focusing on expanding its leadership in GI indications while continuing to grow its cabozantinib business in GU oncology.
EXELIXIS INC (NASDAQ:EXEL) demonstrates a compelling case for investment by combining strong growth fundamentals with a bullish technical setup. The company shows high profitability, sound financial health with no debt, and a firm growth trajectory, making it attractive for growth investors. Technically, EXEL is consolidating within a range, nearing a resistance level, which could signal a new upward trend upon a breakout.
Exelixis (EXEL) is projected to report a significant year-over-year increase in earnings and higher revenues for the quarter ended December 2025. While the company has a strong Zacks Rank of #2, its Earnings ESP of -0.07% suggests that analysts have recently become more bearish, making an earnings beat difficult to predict conclusively. Investors are advised to consider other factors alongside the Earnings ESP and Zacks Rank when evaluating the stock.
Above 50MA
37.18%
Net New Highs
+51081